Evidence for 5-HT2B and 5-HT7 receptor-mediated relaxation in pulmonary arteries of weaned pigs.
This study characterizes the relaxant response to 5-hydroxytryptamine (5-HT) in prostaglandin F(2alpha) (PGF(2alpha))-precontracted pulmonary arteries of weaned pigs. In arterial rings with intact endothelium, the relaxation to 5-HT was biphasic. The high affinity component of relaxation to 5-HT (0.1-10 nM) was abolished by mechanical removal of the endothelium or after the addition of L: -NAME (200 microM), and was inhibited by the 5-HT(2B/2C) receptor antagonist SB 206553 (1 microM), but not the 5-HT(2C) receptor antagonist SB 242084 (0.1 microM). Endothelium-intact arteries were also relaxed by the selective 5-HT(2B) receptor agonist BW 723C86 (pD(2) 7.7). The relaxant response to BW 723C86 was inhibited by 1 microM SB 206553 (pK(B) 6.8). The low affinity component of relaxation to 5-HT (>/=30 nM) remained unaffected after mechanical removal of the endothelium or the addition of L: -NAME. In endothelium-denuded arterial rings, 5-HT, 5-carboxamidotryptamine (5-CT), 5-methoxytryptamine (5-MeOT), and frovatriptan produced monophasic relaxations with pD(2) values of 6.5, 7.5, 5.9, and 4.7 respectively. Relaxant responses to the agonists were antagonized by the selective 5-HT(7) receptor antagonist SB 269970 (pK(B) 8.2-8.9). The relaxant response to the potent 5-HT(7) receptor agonist 5-CT was also antagonized by methiothepin (pK(B) 9.6), pimozide (pK(B) 8.2), mesulergine (pK(B) 7.7), methysergide (pK(B) 7.4), clozapine (pK(B) 7.6), and spiperone (pK(B) 7.4). The estimated pK(B) values argue in favor of an involvement of 5-HT(7) receptors in the direct vasorelaxant action of 5-HT in the pulmonary arteries of weaned pigs. The relaxant response to 5-CT was associated with an increase in cAMP that was surmountably antagonized by SB 269970 (pK(B) 8.6). The present in vitro bioassay can be used to characterize new drugs with potential agonist or antagonist properties at functional 5-HT(7) receptors.
Jähnichen
S
S
Institut für Pharmazie, Freie Universität Berlin, Königin-Luise-Strasse 2+4, 14195 Berlin (Dahlem), Germany.
Glusa
E
E
Pertz
H H
HH
D000465:Algorithms; D000818:Animals; D000242:Cyclic AMP / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology; D066298:In Vitro Techniques; D009126:Muscle Relaxation / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D011651:Pulmonary Artery / Q000187:drug effects / Q000502:physiology*; D011869:Radioligand Assay; D044403:Receptor, Serotonin, 5-HT2B / Q000187:drug effects / Q000502:physiology*; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology*; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D013552:Swine
D044403:Receptor, Serotonin, 5-HT2B; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; C104425:serotonin 7 receptor; D000242:Cyclic AMP
Br J Pharmacol. 1999 Oct;128(3):730-4
10516655
Br J Pharmacol. 1998 Jan;123(2):173-82
9489604
J Neurochem. 1996 Jan;66(1):47-56
8522988
J Med Chem. 2000 Feb 10;43(3):342-5
10669560
Trends Pharmacol Sci. 1997 Apr;18(4):104-7
9149537
Pharmacol Rev. 1995 Jun;47(2):255-66
7568328
Br J Pharmacol Chemother. 1959 Mar;14(1):48-58
13651579
Pharmacol Biochem Behav. 2002 Apr;71(4):533-54
11888546
Trends Pharmacol Sci. 1993 Jul;14(7):270-5
8105597
J Med Chem. 1997 Oct 24;40(22):3494-6
9357513
Br J Pharmacol. 1996 Mar;117(5):926-30
8851512
Br J Pharmacol. 1997 Sep;122(1):126-32
9298538
Am J Physiol Heart Circ Physiol. 2000 Mar;278(3):H907-12
10710360
Br J Pharmacol. 1996 Sep;119(2):330-4
8886417
J Cardiovasc Pharmacol. 1998 Aug;32(2):220-4
9700983
FEBS Lett. 1994 Dec 5;355(3):242-6
7988681
Naunyn Schmiedebergs Arch Pharmacol. 2001 Jun;363(6):620-32
11414657
Behav Brain Res. 1996;73(1-2):263-8
8788515
J Med Chem. 1995 Jul 7;38(14):2524-30
7629791
Br J Pharmacol. 1998 Sep;125(1):69-78
9776346
Br J Pharmacol. 2000 Jun;130(3):539-48
10821781
J Pharmacol Exp Ther. 1996 Jun;277(3):1560-6
8667223
Br J Pharmacol. 1992 Jul;106(3):703-9
1504754
Neuropsychopharmacology. 2003 Mar;28(3):519-26
12629531
Br J Pharmacol. 2000 May;130(1):79-89
10781001
J Pharmacol Exp Ther. 1990 Jan;252(1):387-95
2137176
Br J Pharmacol. 1999 Jun;127(3):609-16
10401550
Behav Brain Res. 1996;73(1-2):149-52
8788493
Br J Pharmacol. 1996 Jul;118(6):1421-8
8832067
Pharmacol Ther. 1994;62(3):283-324
7972337
Br J Pharmacol. 1995 Jan;114(2):400-4
7881740
Naunyn Schmiedebergs Arch Pharmacol. 1993 May;347(5):471-7
8391650
Eur J Pharmacol. 1990 Aug 21;185(1):123-4
2226631
FEBS Lett. 1995 Aug 21;370(3):215-21
7656980
Mol Cell Biochem. 2002 Sep;238(1-2):81-8
12349912
Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):17-24
9459568
J Biol Chem. 1951 Nov;193(1):265-75
14907713
Eur J Neurosci. 1996 May;8(5):959-67
8743744
Br J Pharmacol. 1996 Mar;117(6):993-4
8882587
Br J Pharmacol. 2000 Jun;130(3):692-8
10821800
J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10
7908055
Eur J Pharmacol. 2003 Feb 14;461(2-3):207-18
12586216
Headache. 2002 Apr;42 Suppl 2:S47-53
12028320